13.4 SACUBITRIL/VALSARTAN THERAPY IS ASSOCIATED WITH DECREASE OF PULSE WAVE VELOCITY IN STABLE PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION

13.4 SACUBITRIL/VALSARTAN THERAPY IS ASSOCIATED WITH DECREASE OF PULSE WAVE VELOCITY IN STABLE PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION

Bibliographic Details
Main Authors:	Zhanna Kobalava, Svetlana Villevalde, Olga Lukina
Format:	Article
Language:	English
Published:	BMC 2016-11-01
Series:	Artery Research
Online Access:	https://www.atlantis-press.com/article/125930494/view

Similar Items

13.3 SACUBITRIL/VALSARTAN THERAPY IS ASSOCIATED WITH DECREASE OF ARTERIAL ELASTANCE IN STABLE PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zhanna Kobalava, et al.
Published: (2016-11-01)

EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018-05-01)

EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
by: Zh. D. Kobalava, et al.
Published: (2017-07-01)

11.9 PARAMETERS OF ARTERIAL STIFFNESS HAVE INDEPENDENT PROGNOSTIC VALUE IN STABLE PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Evgeny Tyukhmenev, et al.
Published: (2016-11-01)

11.8 AORTIC SYSTOLIC BLOOD PRESSURE IS NO LONGER MARKER OF THE ARTERIAL STIFFNESS IN STABLE PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Evgeny Tyukhmenev, et al.
Published: (2016-11-01)

Effects and clinical outcomes of early initiation of sacubitril/valsartan in patients with chronic heart failure with a low ejection fraction
by: Z. D. Kobalava, et al.
Published: (2020-12-01)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
by: Muhammad Nauman Khan, et al.
Published: (2023-03-01)

Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction
by: Ruoyu Jia, et al.
Published: (2022-11-01)

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction
by: Ying‐Hsiang Lee, et al.
Published: (2021-04-01)

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
by: Senthil Selvaraj, et al.
Published: (2021-09-01)

Dapagliflozin versus sacubitril–valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024-03-01)

Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan
by: Jawad H. Butt, et al.
Published: (2024-02-01)

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
by: Aldo P. Maggioni, et al.
Published: (2022-12-01)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01)

Starting sacubitril-valsartan is safe in patients with transthyretin cardiac amyloidosis and impaired ejection fraction
by: Martin Negreira-Caamaño, et al.
Published: (2023-02-01)

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
by: Koichiro Matsumura MD, et al.
Published: (2023-01-01)

Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction
by: Zanfina Ademi, et al.
Published: (2017-11-01)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
by: Mauro Gori, et al.
Published: (2021-04-01)

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
by: Stephen J. Greene, et al.
Published: (2021-08-01)

Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction
by: Giovanni Battista Bolla, et al.
Published: (2022-05-01)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
by: Sha Fu, et al.
Published: (2021-06-01)

Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction
by: Matteo Landolfo, et al.
Published: (2020-12-01)

11.10 ARTERIAL ELASTANCE IS ASSOCIATED WITH CENTRAL BLOOD PRESSURE AND ARTERIAL PERIPHERAL RESISTANCE IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Evgeny Tyukhmenev, et al.
Published: (2016-11-01)

Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction
by: Daniele Masarone, et al.
Published: (2020-09-01)

Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction
by: Francesco Giallauria, et al.
Published: (2020-06-01)

Is Sacubitril/Valsartan Able to Change the Timing for Implantation of Cardiac Devices in Heart Failure with Reduced Ejection Fraction?
by: Marta Afonso Nogueira, et al.
Published: (2022-08-01)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
by: Juan Jiang, et al.
Published: (2023-03-01)

Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
by: Mariano A. Giorgi, et al.
Published: (2023-02-01)

Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study
by: Chen Wang, et al.
Published: (2023-06-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
by: Lars H. Lund, et al.
Published: (2022-02-01)

The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients
by: Ji‐Hye Oh, et al.
Published: (2022-08-01)

Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan
by: Po-Lin Lin MD, et al.
Published: (2022-06-01)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
by: Pau Codina, et al.
Published: (2022-08-01)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
by: Charlotte Nordberg Backelin, et al.
Published: (2020-06-01)

Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction
by: Christof Burgdorf, et al.
Published: (2021-10-01)

Sacubitril/Valsartan for heart failure
by: Wenqin Dai, MM, et al.
Published: (2022-06-01)

Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
by: Akihiro Nakamura, et al.
Published: (2023-01-01)

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
by: M Rizzo, et al.
Published: (2020-05-01)

Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)
by: Andrea Di Lenarda, et al.
Published: (2023-01-01)

The Impact of Sacubitril / Valsartan Versus ACE/ARB Therapy on Functional Capacity in Heart Failure with Reduced Ejection Fraction
by: Mohammad Yassen
Published: (2023-05-01)